These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38345715)

  • 1. Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry.
    Baker JF; Zueger P; Ali M; Bennett D; Yu M; Munoz Maldonado Y; McLean RR
    Rheumatol Ther; 2024 Apr; 11(2):363-380. PubMed ID: 38345715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis.
    Harrold LR; Zueger P; Nowell WB; Blachley T; Schrader A; Lakin PR; Curtis D; Stradford L; Venkatachalam S; Tundia N; Patel PA
    Rheumatol Ther; 2023 Dec; 10(6):1519-1533. PubMed ID: 37728861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
    Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
    Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
    Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
    Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
    Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
    Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study.
    Kivitz A; Wells AF; Vargas JI; Baraf HSB; Rischmueller M; Klaff J; Khan N; Li Y; Carter K; Friedman A; Durez P
    Rheumatol Ther; 2023 Aug; 10(4):901-915. PubMed ID: 37199884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States.
    Edgerton C; Frick A; Helfgott S; Huston KK; Singh JA; Zueger P; Anyanwu SI; Patel P; Soloman N
    ACR Open Rheumatol; 2024 Apr; 6(4):179-188. PubMed ID: 38221639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
    Curtis JR; Yun H; Chen L; Ford SS; van Hoogstraten H; Fiore S; Ford K; Praestgaard A; Rehberg M; Choy E
    Rheumatol Ther; 2023 Aug; 10(4):1055-1072. PubMed ID: 37349636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry.
    Pappas DA; O'Brien J; Moore PC; Dodge R; Germino R; Masri KR; Bingham CO; Cappelli LC
    J Rheumatol; 2024 May; 51(5):452-461. PubMed ID: 38359941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry.
    Pappas DA; Blachley T; Zlotnick S; Best J; Emeanuru K; Kremer JM
    Rheumatol Ther; 2020 Jun; 7(2):357-369. PubMed ID: 32232740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.
    Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM
    Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis.
    Reed GW; Gerber RA; Shan Y; Takiya L; Dandreo KJ; Gruben D; Kremer J; Wallenstein G
    Rheumatol Ther; 2019 Nov; 6(4):573-86. PubMed ID: 31707603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are the Goals of Therapy Achievable in Patients with Rheumatoid Arthritis Receiving Upadacitinib in Real Clinical Practice?
    Amirdzhanova VN; Karateev AE; Pogozheva EY; Filatova ES; Samigullina RR; Mazurov VI; Anoshenkova ON; Lapkina NA; Baranov AA; Grineva TY; Lila AM; Nasonov EL
    Dokl Biochem Biophys; 2023 Aug; 511(1):180-186. PubMed ID: 37833604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Young P; Fallon L; Mundayat R; Dina O; Blachley T; Middaugh N; Ogdie A
    Rheumatol Ther; 2024 Apr; 11(2):313-329. PubMed ID: 38252211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V; Tundia N; Wells A; Buch MH; Radominski SC; Camp HS; Friedman A; Suboticki JL; Dunlap K; Goldschmidt D; Bergman M
    Rheumatology (Oxford); 2021 Jul; 60(7):3209-3221. PubMed ID: 33313898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
    Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.
    Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM
    Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.
    Pappas DA; Kremer JM; Griffith J; Reed G; Salim B; Karki C; Garg V
    Rheumatol Ther; 2017 Dec; 4(2):375-389. PubMed ID: 28840531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.
    Harrold LR; John A; Reed GW; Haselkorn T; Karki C; Li Y; Best J; Zlotnick S; Kremer JM; Greenberg JD
    Rheumatol Ther; 2017 Dec; 4(2):405-417. PubMed ID: 28936808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.